Seeking Alpha

Buy the rumor, sell the news: after a 3 week rally, Optimer Pharmaceutical (OPTR -7.2%) sells...

Buy the rumor, sell the news: after a 3 week rally, Optimer Pharmaceutical (OPTR -7.2%) sells off hard after winning FDA approval for its antibiotic drug Dificid for treatment of Clostridium Difficel-Associated infections.
Comments (1)
  • HIGHWATER 888
    , contributor
    Comments (315) | Send Message
     
    Comment? I'm looking for some insight. All I can say with certainty is that someone began heavy selling at 3:26 PM. The FDA approval was all good. Did someone push the stop loss orders? Did a hedge fund misread the FDA approval? After market trading regained most of the lost ground, but still below the key $14 BB.

     

    Either I'm misreading the FDA approval, or OPTR became crazy cheap for about 20 minutes on Friday. IMO, OPTR, post approval is worth $17-18 per share but will be watching the price action closely on Tuesday.
    29 May 2011, 12:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector